Audit: QRS - Thymosin Alpha-1 for Health & Longevity
Audit conducted on 02/07/2026 15:02 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 91 |
| Failed | 0 |
| N/A | 0 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to the ER (dose/route from Protocol L311; form from Sourcing L353; benefits/risks/monitoring from their respective ER sections). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “unproven”, “uncertain”, “theoretical overstimulation”, “unknown long-term” mirror ER cautious phrasing. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy/breastfeeding kept as a contraindication (avoid), matching ER L291; no strengthening or softening detected. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications/Interactions drawn from the ER “Key Interactions & Contraindications” section; no modifying-factor content miscategorised. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | QRS carries no PMIDs, NCT IDs, expert names, or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, evidence-forward tone matches the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging. | 🟢 | Expert yet accessible; balanced framing throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor. | 🟢 | Presents evidence without prescribing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice. | 🟢 | No directive/advisory phrasing; footer disclaimer present. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”. | 🟢 | Content is presented, not recommended. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance. | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon. | 🟢 | Plain-language phrasing throughout. |
| 2.8 | Information is presented in a concise and very compact manner. | 🟢 | Compact card/table layout. |
| 2.9 | It DOES NOT address the reader directly. | 🟢 | No direct reader address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing targets the risk-aware longevity reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol/monitoring detail assumes a committed reader. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not written for the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Distinguishes immune-depleted vs already-healthy signal. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | Uses “longevity”/”healthy-aging”; no “anti-aging” in the QRS voice. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Uses “injection”, “subcutaneous”, “adverse” register; no consumer-grade terms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); gate headings (“Contraindications”, “Key Interactions”); tier labels (“High”, “Medium”, “Low”, “Speculative”); table column headers (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings/labels present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the QRS. | 🟢 | All expected data-qrs-var spans present. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged. | 🟢 | No unaddressed spans altered. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | 🟢 | No source sections were empty; all populated with real content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Benefit/risk tiers and monitoring markers use ER labels faithfully. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels match ER wording. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators; ER’s tier emojis were dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to fit a single-page layout. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element after doctype (L2-14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but not parsed as YAML. | 🟢 | YAML delimited by — at L3 and L13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value requires YAML quoting. | 🟢 | Values clean; duration quoted appropriately for the colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]”. | 🟢 | er_filename: thymosin_alpha_1_2026-0702-1244_Opus_ER.md (L4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”. | 🟢 | qrs_prompt_version: 26.7.02 (L5). |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. | 🟢 | qrs_creation_date: 2026-0702-1244 (L6). |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”. | 🟢 | qrs_creator_ai_nickname: Opus (L7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus” is a single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”. | 🟢 | qrs_creator_ai_fullname: Opus 4.8 (L8). |
| 5.11 | The full name of the AI consists of the nickname and the model version number and no additional qualifier. | 🟢 | “Opus 4.8” has no extra qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]”. | 🟢 | qrs_filename: thymosin_alpha_1_2026-0702-1244_Opus_QRS.html (L9). |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless required by YAML. | 🟢 | Consistent, trimmed values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Thymosin Alpha-1 for Health & Longevity - Quick Reference Sheet” (L22). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Thymosin Alpha-1 for Health & Longevity” (L417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. | 🟢 | 07/02/2026 (L421), correct for 2026-0702. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname]. | 🟢 | “Opus 4.8” (L425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and standard subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section. | 🟢 | Distils the ER Conclusion (L420-424). |
| 7.2 | [at_a_glance] is no longer than 60 words. | 🟢 | 51 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Balancer framing, prescription-abroad use, immune-restoration, vaccine response, unproven longevity, quality/legal uncertainty all appear in the Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge; uses plain-language terms instead. | 🟢 | Plain-language throughout; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values). | 🟢 | No trials cited. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results. | 🟢 | No statistics cited. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section. | 🟢 | Drawn from ER L279-291. |
| 8.2 | [stop_items] represent the Contraindications from the ER. | 🟢 | Maps to the “Populations who should avoid it” bullet (L291). |
| 8.3 | Individual [stop_items] are formatted as <li></li>. | 🟢 | Four <li> items (L542-545). |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details. No content after an em/en/hyphen-dash. | 🟢 | Items terminate cleanly; no trailing dash clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | “first 6–12 months post-transplant or during active rejection” and “flaring or systemically active” preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>”) that depends on an explanatory phrase, normalize to a plain comma-separated list rather than carrying the bare symbol. | 🟢 | No ranking symbols present; lists are plain comma-separated. |
| 8.7 | If no [stop_items] are present the section is left empty. | 🟢 | Contraindications are present; section populated. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section. | 🟢 | Drawn from ER L281-289. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications. | 🟢 | Interferons, immunosuppressants, checkpoint inhibitors, immune-stimulating supplements; beneficial Vaccines interaction correctly excluded. |
| 9.3 | Individual [caution_items] are formatted as <li></li>. | 🟢 | Four <li> items (L553-556). |
| 9.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details. No content after an em/en/hyphen-dash. | 🟢 | Items terminate cleanly; no trailing dash clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, thresholds, staging — ARE preserved, kept concise. | 🟢 | Example-drug parentheticals preserved (e.g., tacrolimus, cyclosporine; pembrolizumab, nivolumab; echinacea, beta-glucans). |
| 9.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list. | 🟢 | No ranking symbols present; plain lists used. |
| 9.7 | If no [caution_items] are present the section is left empty. | 🟢 | Key Interactions present; section populated. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section. | 🟢 | Drawn from ER Therapeutic Protocol (L309-331) and Sourcing (L353). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section. | 🟢 | Dose & Route, Course Length, Form. |
| 10.3 | If less than three distinct actionable aspects are mentioned, unused sets are left empty and invisible, not filled with placeholder text. | 🟢 | All three sets are legitimately used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. | 🟢 | 1.6 mg SC twice weekly / 6–12 months / reconstituted injection all match the ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER. | 🟢 | Immune markers (weeks), viral control (months), vaccine response (around vaccination). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit. | 🟢 | Ordered from the strongest/most-consistent immune effect outward. |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and invisible, not filled with placeholder text. | 🟢 | Three legitimate aspects used; no placeholders. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Values trace to ER L362 (weeks/months) and L167/L287 (vaccine timing). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel. | 🟢 | ER provides time-to-effect info (L362); section retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section. | 🟢 | Drawn from ER L149-199. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. | 🟢 | All four tiers populated. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations. | 🟢 | Short tier phrases only. |
| 12.4 | Parenthetical content — effect sizes, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | “(Subgroup-Dependent)” and other parentheticals stripped from tier items. |
| 12.5 | If no items of a specific sub-section are present the respective SPAN is set to “display=none”, not filled with empty-state phrasing. | 🟢 | All four tiers have real content; no empty-state phrasing used. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section. | 🟢 | Drawn from ER L215-259. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. | 🟢 | All four tiers populated. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations. | 🟢 | Short tier phrases only. |
| 13.4 | Parenthetical content — frequencies, severity grades, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried into risk items. |
| 13.5 | If no items of a specific sub-section are present the respective SPAN is set to “display=none”, not filled with empty-state phrasing. | 🟢 | All four tiers have real content; no empty-state phrasing used. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section. | 🟢 | Drawn from ER Monitoring Protocol table (L386-393). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed. | 🟢 | All six markers present with matching targets (CD4/CD8, CD4+, lymphocytes, hs-CRP, neutrophils, glucose/HbA1c). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency from the ER Monitoring section. Not placeholder or empty. | 🟢 | Baseline → ~4–8 weeks → every 3–6 months, matching ER L384. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section. | 🟢 | Drawn from ER qualitative markers (L397-400). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed. | 🟢 | All four qualitative markers present. |
Issues 02/07/2026 15:02
Pass rate 100.00%. No issues found.